KARACHI: The Directorate General of Customs Valuation in Karachi announced the revision covering pharmaceutical-grade glass imports from China and Europe.
The new ruling replaces an earlier valuation that was withdrawn following stakeholder appeals, which prompted authorities to conduct a fresh review of prevailing price levels.
Importers had raised concerns that the previous customs benchmarks were misaligned with actual international market prices, noting in particular that the declared import value of clear glass ampoules from China had fallen below earlier reference points.
Pricing differences between printed and non-printed ampoules were also highlighted during consultations, though limited trade data was available for printed variants.
Customs officials confirmed that all importer submissions and supporting documentation were considered during the valuation exercise. A market survey found that glass ampoules and glass tubing — being specialized industrial inputs for pharmaceutical manufacturing — are not domestically produced or widely available in Pakistan, which restricted direct local price comparisons.
Authorities also examined alternative valuation methods but determined they could not be reliably applied, citing insufficient data on manufacturing and conversion costs in the exporting countries.
The revised valuation is intended to bring import duty assessment closer to actual trade prices, improving accuracy and transparency for pharmaceutical manufacturers and importers of injectable packaging materials.
The ruling covers imports from China and Europe and has been issued under the authority of the Directorate General of Customs Valuation, Karachi.
